These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 11372896)

  • 21. Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
    Prescrire Int; 2004 Aug; 13(72):135-7. PubMed ID: 15532137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
    Carmosino I; Latagliata R; Avvisati G; Breccia M; Finolezzi E; Lo Coco F; Petti MC
    Haematologica; 2004 May; 89(5):615-7. PubMed ID: 15136230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A modern application for an ancient remedy.
    Datta K
    Natl Med J India; 1998; 11(6):277-9. PubMed ID: 10083796
    [No Abstract]   [Full Text] [Related]  

  • 24. Arsenic-induced APL differentiation in cerebrospinal fluid.
    Helwig A; Klemm M; Schüttig R; Röllig C; Wassilew N; Ehninger G; Illmer T
    Leuk Res; 2007 May; 31(5):703-5. PubMed ID: 16876245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The revival of the ancient drug--arsenic.
    Huang X
    Chin Med J (Engl); 2003 Nov; 116(11):1637-8. PubMed ID: 14642126
    [No Abstract]   [Full Text] [Related]  

  • 26. Arsenic trioxide in the management of acute promyelocytic leukaemia.
    Mathews V; Chandy M; Srivastava A
    Natl Med J India; 2001; 14(4):215-22. PubMed ID: 11547528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia.
    Au WY; Kumana CR; Lam CW; Cheng VC; Shek TW; Chan EY; Liu R; Kwong YL
    Leuk Res; 2007 Jan; 31(1):105-8. PubMed ID: 16725199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arsenic-based therapy benefits leukemia patients.
    FDA Consum; 2001; 35(1):4. PubMed ID: 11930925
    [No Abstract]   [Full Text] [Related]  

  • 29. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
    Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
    Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chinese folk treatment reveals power of arsenic to treat cancer, new studies under way.
    Hede K
    J Natl Cancer Inst; 2007 May; 99(9):667-8. PubMed ID: 17470732
    [No Abstract]   [Full Text] [Related]  

  • 31. Use of arsenic trioxide as a first-line single agent in the treatment of acute promyelocytic leukemia.
    Keyhani M
    J Clin Oncol; 2012 Jan; 30(2):217; author reply 218-20; discussion 220-2. PubMed ID: 22124099
    [No Abstract]   [Full Text] [Related]  

  • 32. Anion exchanger 2 mediates the action of arsenic trioxide.
    Pan XY; Chen GQ; Cai L; Buscemi S; Fu GH
    Br J Haematol; 2006 Sep; 134(5):491-9. PubMed ID: 17018029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
    Douer D; Tallman MS
    J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.
    Mathews V; Balasubramanian P; Shaji RV; George B; Chandy M; Srivastava A
    Am J Hematol; 2002 Aug; 70(4):292-9. PubMed ID: 12210810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia.
    Carney DA
    Leuk Lymphoma; 2008 Oct; 49(10):1846-51. PubMed ID: 18949607
    [No Abstract]   [Full Text] [Related]  

  • 36. What is the role of arsenic in newly diagnosed APL?
    Tallman MS
    Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
    Au WY; Tam S; Kwong YL
    Leuk Res; 2008 Feb; 32(2):357-8. PubMed ID: 17662385
    [No Abstract]   [Full Text] [Related]  

  • 38. Early relapse after non myeloablative allogeneic stem cell transplantation in a patient with acute promyelocytic leukemia in complete molecular remission.
    Tavernier E; Thomas X
    Indian J Cancer; 2003; 40(4):140-3. PubMed ID: 14716110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy.
    Ninomiya M; Kajiguchi T; Yamamoto K; Kinoshita T; Emi N; Naoe T
    Haematologica; 2006 Nov; 91(11):1571-2. PubMed ID: 17082016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Barbey JT; Pezzullo JC; Soignet SL
    J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.